07:39 AM EDT, 03/10/2025 (MT Newswires) -- Trevi Therapeutics ( TRVI ) said Monday a phase 2a trial of its investigational drug Haduvio met the primary endpoint of a statistically significant reduction in 24-hour cough frequency in patients with refractory chronic cough.

The company said Haduvio, or oral nalbuphine ER, achieved a reduction in 24-hour cough count of 67% from baseline and 57% on a placebo-adjusted basis at day 21.

Trevi said it plans to discuss the next steps with the US Food and Drug Administration and expects to initiate the next study after receiving the regulator's feedback.

Shares of the company rose more than 32% in recent premarket activity.